{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:01:48Z","timestamp":1772697708664,"version":"3.50.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurogenetics"],"DOI":"10.1007\/s10048-025-00848-1","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:52:36Z","timestamp":1757134356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Huntington\u2019s chorea: emerging fields in therapeutics (Review)"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7792-7125","authenticated-orcid":false,"given":"Aisha","family":"Tahir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sania","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usman Ali","family":"Shams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saqib","family":"Mehmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"issue":"no. 5","key":"848_CR1","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","volume":"89","author":"F Saudou","year":"2016","unstructured":"Saudou F, Humbert S (2016) The biology of huntingtin. Neuron 89(5):910\u2013926","journal-title":"Neuron"},{"issue":"10","key":"848_CR2","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","volume":"84","author":"SJ Evans","year":"2013","unstructured":"Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L (2013) Prevalence of adult huntington\u2019s disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry 84(10):1156\u20131160","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"848_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153","author":"DR Langbehn","year":"2010","unstructured":"Langbehn DR, Hayden MR, Paulsen JS (2010) I. O. T. H. S. Group, CAG-repeat length and T.e age O. O.set in huntington disease (HD): a review and validation study O. statistical approaches. Am J Med Genet Part B: Neuropsychiatric Genet 153(2):397\u2013408","journal-title":"Am J Med Genet Part B: Neuropsychiatric Genet"},{"issue":"4","key":"848_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10(4):204\u2013216","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"848_CR5","doi-asserted-by":"publisher","first-page":"e1000304","DOI":"10.1371\/journal.pcbi.1000304","volume":"5","author":"GA Palidwor","year":"2009","unstructured":"Palidwor GA et al (2009) Detection of alpha-rod protein repeats using a neural network and application to Huntingtin. PLoS Comput Biol 5(3):e1000304","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"848_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/molbev\/msm258","volume":"25","author":"M Tartari","year":"2008","unstructured":"Tartari M et al (2008) Phylogenetic comparison of Huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. Mol Biol Evol 25(2):330\u2013338","journal-title":"Mol Biol Evol"},{"issue":"9","key":"848_CR7","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1074\/jbc.M112.413575","volume":"288","author":"Z Zheng","year":"2013","unstructured":"Zheng Z, Li A, Holmes BB, Marasa JC, Diamond MI (2013) An N-terminal nuclear export signal regulates trafficking and aggregation of Huntingtin (Htt) protein exon 1. J Biol Chem 288(9):6063\u20136071","journal-title":"J Biol Chem"},{"issue":"1","key":"848_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0169-328X(95)00124-B","volume":"33","author":"DA Bessert","year":"1995","unstructured":"Bessert DA, Gutridge KL, Dunbar JC, Carlock LR (1995) The identification of a functional nuclear localization signal in the huntington disease protein. Mol Brain Res 33(1):165\u2013173","journal-title":"Mol Brain Res"},{"issue":"12","key":"848_CR9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/hmg\/ddg156","volume":"12","author":"J Xia","year":"2003","unstructured":"Xia J, Lee DH, Taylor J, Vandelft M, Truant R (2003) Huntingtin contains a highly conserved nuclear export signal. Hum Mol Genet 12(12):1393\u20131403","journal-title":"Hum Mol Genet"},{"issue":"5","key":"848_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","volume":"81","author":"J Nasir","year":"1995","unstructured":"Nasir J et al (1995) Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81(5):811\u2013823","journal-title":"Cell"},{"issue":"no. 4","key":"848_CR11","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/brain\/awn025","volume":"131","author":"HD Rosas","year":"2008","unstructured":"Rosas HD et al (2008) Cerebral cortex and the clinical expression of Huntington\u2019s disease: complexity and heterogeneity. Brain 131(4):1057\u20131068","journal-title":"Brain"},{"issue":"5334","key":"848_CR12","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia M et al (1997) Aggregation of Huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277(5334):1990\u20131993","journal-title":"Science"},{"issue":"3","key":"848_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/ajmg.a.20190","volume":"119","author":"L Djouss\u00e9","year":"2003","unstructured":"Djouss\u00e9 L et al (2003) Interaction of normal and expanded CAG repeat sizes influences age at onset of huntington disease. Am J Med Genet Part A 119(3):279\u2013282","journal-title":"Am J Med Genet Part A"},{"issue":"4","key":"848_CR14","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1136\/jmg.38.4.e12","volume":"38","author":"A MAAT-KIEVIT","year":"2001","unstructured":"MAAT-KIEVIT A et al (2001) New problems in testing for huntington\u2019s disease: the issue of intermediate and reduced penetrance alleles. J Med Genet 38(4):e12\u2013e12","journal-title":"J Med Genet"},{"issue":"9369","key":"848_CR15","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/S0140-6736(03)13304-1","volume":"361","author":"G Bates","year":"2003","unstructured":"Bates G (2003) Huntingtin aggregation and toxicity in huntington\u2019s disease. Lancet 361(9369):1642\u20131644","journal-title":"Lancet"},{"issue":"1","key":"848_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP et al (2015) Huntington disease. Nat Rev Dis Primers 1(1):1\u201321","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"848_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mds.25717","volume":"29","author":"ER Fisher","year":"2014","unstructured":"Fisher ER, Hayden MR (2014) Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord 29(1):105\u2013114","journal-title":"Mov Disord"},{"issue":"1","key":"848_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000337680","volume":"68","author":"\u00d3 Sveinsson","year":"2012","unstructured":"Sveinsson \u00d3, Halld\u00f3rsson S, Olafsson E (2012) An unusually low prevalence of Huntington\u2019s disease in Iceland. Eur Neurol 68(1):48\u201351","journal-title":"Eur Neurol"},{"issue":"1","key":"848_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.parkreldis.2014.10.025","volume":"21","author":"JO Sipil\u00e4","year":"2015","unstructured":"Sipil\u00e4 JO, Hietala M, Siitonen A, P\u00e4iv\u00e4rinta M, Majamaa K (2015) Epidemiology of Huntington\u2019s disease in Finland. Parkinsonism Relat Disord 21(1):46\u201349","journal-title":"Parkinsonism Relat Disord"},{"key":"848_CR20","doi-asserted-by":"crossref","unstructured":"Squitieri F, Elifani F, Di Pardo A, Porcellini A, D\u2019Alessio B (2014) K12 epidemiology of huntington disease: first Post-htt gene analysis of prevalence in Italy. BMJ Publishing Group Ltd","DOI":"10.1136\/jnnp-2014-309032.236"},{"issue":"1","key":"848_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ (2018) Huntington\u2019s disease: a clinical review. Eur J Neurol 25(1):24\u201334","journal-title":"Eur J Neurol"},{"key":"848_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314597.127","author":"CA Ross","year":"2016","unstructured":"Ross CA, Reilmann R (2016) E1 diagnostic criteria for huntington\u2019s disease based on natural history. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2016-314597.127","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"18","key":"848_CR23","doi-asserted-by":"publisher","first-page":"e2101","DOI":"10.1212\/WNL.0000000000007147","volume":"92","author":"E Cubo","year":"2019","unstructured":"Cubo E et al (2019) Clinical manifestations of homozygote allele carriers in Huntington disease. Neurology 92(18):e2101\u2013e2108","journal-title":"Neurology"},{"issue":"1","key":"848_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-012857","volume":"14","author":"AP Lieberman","year":"2019","unstructured":"Lieberman AP, Shakkottai VG, Albin RL (2019) Polyglutamine repeats in neurodegenerative diseases. Annu Rev Pathol 14(1):1\u201327","journal-title":"Annu Rev Pathol"},{"key":"848_CR25","doi-asserted-by":"publisher","unstructured":"Lin Y, Wilson JH (2012) Nucleotide excision repair, mismatch repair, and R-loops modulate convergent transcription-induced cell death and repeat instability. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0046807","DOI":"10.1371\/journal.pone.0046807"},{"issue":"2","key":"848_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003280","volume":"9","author":"S Tom\u00e9","year":"2013","unstructured":"Tom\u00e9 S et al (2013) MSH3 polymorphisms and protein levels affect CAG repeat instability in huntington\u2019s disease mice. PLoS Genet 9(2):e1003280","journal-title":"PLoS Genet"},{"issue":"7","key":"848_CR27","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archneur.63.7.991","volume":"63","author":"HSGP Investigators","year":"2006","unstructured":"Investigators HSGP (2006) At risk for huntington disease: the PHAROS (Prospective huntington at risk observational Study) cohort enrolled. Arch Neurol 63(7):991\u2013996","journal-title":"Arch Neurol"},{"issue":"2","key":"848_CR28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mdc3.12388","volume":"4","author":"GB Landwehrmeyer","year":"2017","unstructured":"Landwehrmeyer GB et al (2017) Data analytics from Enroll-HD, a global clinical research platform for huntington\u2019s disease. Mov Disord Clin Pract 4(2):212\u2013224","journal-title":"Mov Disord Clin Pract"},{"key":"848_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.conb.2015.01.020","volume":"33","author":"JL Plotkin","year":"2015","unstructured":"Plotkin JL, Surmeier DJ (2015) Corticostriatal synaptic adaptations in Huntington\u2019s disease. Curr Opin Neurobiol 33:53\u201362","journal-title":"Curr Opin Neurobiol"},{"issue":"52","key":"848_CR30","doi-asserted-by":"publisher","first-page":"22480","DOI":"10.1073\/pnas.0911503106","volume":"106","author":"J Bradford","year":"2009","unstructured":"Bradford J, Shin J-Y, Roberts M, Wang C-E, Li X-J, Li S (2009) Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A 106(52):22480\u201322485","journal-title":"Proc Natl Acad Sci U S A"},{"key":"848_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fncir.2013.00019","volume":"7","author":"AM Estrada-S\u00e1nchez","year":"2013","unstructured":"Estrada-S\u00e1nchez AM, Rebec GV (2013) Role of cerebral cortex in the neuropathology of huntington\u2019s disease. Front Neural Circuits 7:19","journal-title":"Front Neural Circuits"},{"issue":"4","key":"848_CR32","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/brain\/awq047","volume":"133","author":"DC Thu","year":"2010","unstructured":"Thu DC et al (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington\u2019s disease. Brain 133(4):1094\u20131110","journal-title":"Brain"},{"issue":"12","key":"848_CR33","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/mds.29228","volume":"37","author":"A Medina","year":"2022","unstructured":"Medina A, Mahjoub Y, Shaver L, Pringsheim T (2022) Prevalence and incidence of huntington\u2019s disease: an updated systematic review and meta-analysis. Mov Disord 37(12):2327\u20132335","journal-title":"Mov Disord"},{"key":"848_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2024.102823","volume":"105","author":"UA Shams","year":"2024","unstructured":"Shams UA et al (2024) Bio-net dataset: AI-based diagnostic solutions using peripheral blood smear images. Blood Cells Mol Dis 105:102823","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"848_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.15406\/japlr.2018.07.00256","volume":"7","author":"F Khan","year":"2018","unstructured":"Khan F, Garg VK, Singh AK, Kumar T (2018) Role of free radicals and certain antioxidants in the management of Huntington\u2019s disease: a review. J Anal Pharm Res 7(4):386\u2013392","journal-title":"J Anal Pharm Res"},{"issue":"2","key":"848_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009070","volume":"6","author":"NS Wexler","year":"2016","unstructured":"Wexler NS et al (2016) Incidence of adult Huntington\u2019s disease in the UK: a UK-based primary care study and a systematic review. BMJ Open 6(2):e009070","journal-title":"BMJ Open"},{"issue":"1\u20132","key":"848_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000479697","volume":"49","author":"E Carrassi","year":"2017","unstructured":"Carrassi E, Pugliatti M, Govoni V, Sensi M, Casetta I, Granieri E (2017) Epidemiological study of Huntington\u2019s disease in the province of Ferrara, Italy. Neuroepidemiology 49(1\u20132):18\u201323","journal-title":"Neuroepidemiology"},{"key":"848_CR38","first-page":"56","volume":"13440","author":"UA Shams","year":"2024","unstructured":"Shams UA, Javed I, Naveed MA, Mehmood MQ (2024) AI-empowered blood cell analysis using customized dataset, in Fourth iiScience International Conference 2024: Recent Advances in Photonics and Physical Sciences. SPIE 13440:56\u201363","journal-title":"SPIE"},{"key":"848_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00453","volume":"10","author":"S Migliore","year":"2019","unstructured":"Migliore S, Jankovic J, Squitieri F (2019) Genetic counseling in huntington\u2019s disease: potential new challenges on horizon? Front Neurol 10:453","journal-title":"Front Neurol"},{"issue":"6","key":"848_CR40","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/ana.24656","volume":"79","author":"C Bettencourt","year":"2016","unstructured":"Bettencourt C et al (2016) DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. Ann Neurol 79(6):983\u2013990","journal-title":"Ann Neurol"},{"issue":"2","key":"848_CR41","first-page":"5","volume":"8","author":"UA Shams","year":"2023","unstructured":"Shams UA, Zeb MA, Karim WA, Azhar M, ul Haq F (2023) Impact of hypothyroidism and lipid profile on obesity. Asian J Allied Health Sci (AJAHS) 8(2):5\u201313","journal-title":"Asian J Allied Health Sci (AJAHS)"},{"issue":"2","key":"848_CR42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ana.24694","volume":"80","author":"MK Singh-Bains","year":"2016","unstructured":"Singh-Bains MK et al (2016) Globus pallidus degeneration and clinicopathological features of huntington disease. Ann Neurol 80(2):185\u2013201","journal-title":"Ann Neurol"},{"key":"848_CR43","first-page":"23","volume":"12","author":"I Dogan","year":"2013","unstructured":"Dogan I et al (2013) \u201cConsistent neurodegeneration and its association with clinical progression in Huntington\u2019s disease: a coordinate-based meta-analysis,.\u201d S. Karger AG Basel, Switzerland 12:23\u201325","journal-title":"S. Karger AG Basel, Switzerland"},{"key":"848_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.05.015","volume":"307","author":"SJ van den Bogaard","year":"2011","unstructured":"van den Bogaard SJ et al (2011) Shape analysis of subcortical nuclei in huntington\u2019s disease, global versus local atrophy\u2014Results from the TRACK-HD study. J Neurol Sci 307:1\u20132","journal-title":"J Neurol Sci"},{"issue":"17","key":"848_CR45","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1073\/pnas.1702237114","volume":"114","author":"M Chen","year":"2017","unstructured":"Chen M, Wolynes PG (2017) Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington\u2019s disease. Proc Natl Acad Sci U S A 114(17):4406\u20134411","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"848_CR46","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s12035-014-8715-8","volume":"51","author":"LM Valor","year":"2015","unstructured":"Valor LM (2015) Transcription, epigenetics and ameliorative strategies in huntington\u2019s disease: a genome-wide perspective. Mol Neurobiol 51(1):406\u2013423","journal-title":"Mol Neurobiol"},{"issue":"4","key":"848_CR47","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nsmb1215","volume":"14","author":"Y Nagai","year":"2007","unstructured":"Nagai Y et al (2007) A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol 14(4):332\u2013340","journal-title":"Nat Struct Mol Biol"},{"key":"848_CR48","unstructured":"Mears E (2018) Investigating the Molecular Mechanisms of Huntington\u2019s Disease. University of Auckland"},{"issue":"no. 9246","key":"848_CR49","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","volume":"356","author":"A-C Bachoud-L\u00e9vi","year":"2000","unstructured":"Bachoud-L\u00e9vi A-C et al (2000) Motor and cognitive improvements in patients with Huntington\u2019s disease after neural transplantation. Lancet 356(9246):1975\u20131979","journal-title":"Lancet"},{"key":"848_CR50","unstructured":"Vonsattel J, DiFiglia M (1997) Huntington disease"},{"issue":"2","key":"848_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm0202-143","volume":"8","author":"MV Karpuj","year":"2002","unstructured":"Karpuj MV et al (2002) Prolonged survival and decreased abnormal movements in transgenic model of huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8(2):143\u2013149","journal-title":"Nat Med"},{"issue":"no. 10","key":"848_CR52","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1212\/WNL.0b013e318249f683","volume":"78","author":"J-M Lee","year":"2012","unstructured":"Lee J-M et al (2012) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78(10):690\u2013695","journal-title":"Neurology"},{"issue":"5","key":"848_CR53","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2217\/rme.15.25","volume":"10","author":"KD Fink","year":"2015","unstructured":"Fink KD et al (2015) Developing stem cell therapies for juvenile and adult-onset huntington\u2019s disease. Regen Med 10(5):623\u2013646","journal-title":"Regen Med"},{"issue":"6613","key":"848_CR54","doi-asserted-by":"publisher","first-page":"eabq5011","DOI":"10.1126\/science.abq5011","volume":"377","author":"BY Braz","year":"2022","unstructured":"Braz BY et al (2022) Treating early postnatal circuit defect delays Huntington\u2019s disease onset and pathology in mice. Science 377(6613):eabq5011","journal-title":"Science"},{"key":"848_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.redox.2015.02.002","volume":"4","author":"KL Berggren","year":"2015","unstructured":"Berggren KL et al (2015) Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6\/2 mouse model of huntington\u2019s disease. Redox Biol 4:363\u2013374","journal-title":"Redox Biol"},{"issue":"16","key":"848_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168363","volume":"22","author":"A Kim","year":"2021","unstructured":"Kim A et al (2021) New avenues for the treatment of huntington\u2019s disease. Int J Mol Sci 22(16):8363","journal-title":"Int J Mol Sci"},{"issue":"3\u20134","key":"848_CR57","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.3171\/FOC\/2008\/24\/3-4\/E8","volume":"24","author":"CD Clelland","year":"2008","unstructured":"Clelland CD, Barker RA, Watts C (2008) Cell therapy in Huntington disease. Neurosurg Focus 24(3\u20134):E9","journal-title":"Neurosurg Focus"},{"issue":"2","key":"848_CR58","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.nbd.2011.12.030","volume":"48","author":"S Ramaswamy","year":"2012","unstructured":"Ramaswamy S, Kordower JH (2012) Gene therapy for huntington\u2019s disease. Neurobiol Dis 48(2):243\u2013254","journal-title":"Neurobiol Dis"},{"issue":"9","key":"848_CR59","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/stem.1135","volume":"30","author":"I Jeon","year":"2012","unstructured":"Jeon I et al (2012) Neuronal properties, in vivo effects, and pathology of a Huntington\u2019s disease patient-derived induced pluripotent stem cells. Stem Cells 30(9):2054\u20132062","journal-title":"Stem Cells"},{"issue":"3","key":"848_CR60","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1602\/neurorx.2.3.447","volume":"2","author":"JY Li","year":"2005","unstructured":"Li JY, Popovic N, Brundin P (2005) The use of the R6 transgenic mouse models of Huntington\u2019s disease in attempts to develop novel therapeutic strategies. NeuroRx 2(3):447\u2013464","journal-title":"NeuroRx"},{"issue":"2","key":"848_CR61","first-page":"e060217","volume":"6","author":"A Choudhary","year":"2017","unstructured":"Choudhary A, Minocha P, Sitaraman S (2017) A case report of juvenile huntington disease. J Pediatr Neonat Individual Med 6(2):e060217\u2013e060217","journal-title":"J Pediatr Neonat Individual Med"},{"issue":"6","key":"848_CR62","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3390\/jcm9062004","volume":"9","author":"K Dhuri","year":"2004","unstructured":"Dhuri K et al (2004) Antisense oligonucleotides: an emerging area in drug discovery and development. Journal of clinical medicine 9(6):2004\u20132020","journal-title":"Journal of clinical medicine"},{"issue":"1","key":"848_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-06121-9","volume":"7","author":"V Baylot","year":"2024","unstructured":"Baylot V, Le TK, Ta\u00efeb D, Rocchi P, Colleaux L (2024) Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs. Commun Biol 7(1):489","journal-title":"Commun Biol"},{"issue":"2","key":"848_CR64","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1172\/JCI45364","volume":"121","author":"I Munoz-Sanjuan","year":"2011","unstructured":"Munoz-Sanjuan I, Bates GP (2011) The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest 121(2):476\u2013483","journal-title":"J Clin Invest"},{"issue":"4","key":"848_CR65","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/ajmg.a.38494","volume":"176","author":"AS Dickey","year":"2018","unstructured":"Dickey AS, La Spada AR (2018) Therapy development in huntington disease: from current strategies to emerging opportunities. Am J Med Genet A 176(4):842\u2013861","journal-title":"Am J Med Genet A"},{"issue":"3","key":"848_CR66","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/BF00225192","volume":"95","author":"KE De Rooij","year":"1995","unstructured":"De Rooij KE, De Koning Gans PA, Roos RA, Van Ommen G-JB (1995) Den dunnen, somatic expansion of the (CAG) n repeat in huntington disease brains. Hum Genet 95(3):270\u2013274","journal-title":"Hum Genet"},{"issue":"5","key":"848_CR67","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jmg.31.5.377","volume":"31","author":"Y Trottier","year":"1994","unstructured":"Trottier Y, Biancalana V, Mandel J-L (1994) Instability of CAG repeats in huntington\u2019s disease: relation to parental transmission and age of onset. J Med Genet 31(5):377\u2013382","journal-title":"J Med Genet"},{"key":"848_CR68","doi-asserted-by":"crossref","unstructured":"Eid AM, Faridar A, Appel SH (2024) Therapeutic strategies in neurodegenerative diseases. Neuroimmune Pharmacology and therapeutics. Springer, pp 671\u2013704","DOI":"10.1007\/978-3-031-68237-7_39"},{"issue":"23","key":"848_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312485","volume":"25","author":"N Garc\u00eda-Gonz\u00e1lez","year":"2024","unstructured":"Garc\u00eda-Gonz\u00e1lez N, Gon\u00e7alves-S\u00e1nchez J, G\u00f3mez-Nieto R, Gon\u00e7alves-Estella JM, L\u00f3pez DE (2024) Advances and challenges in gene therapy for neurodegenerative diseases: a systematic review. Int J Mol Sci 25(23):12485","journal-title":"Int J Mol Sci"},{"issue":"22","key":"848_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212499","volume":"22","author":"C Kim","year":"2021","unstructured":"Kim C, Yousefian-Jazi A, Choi S-H, Chang I, Lee J, Ryu H (2021) Non-cell autonomous and epigenetic mechanisms of huntington\u2019s disease. Int J Mol Sci 22(22):12499","journal-title":"Int J Mol Sci"},{"issue":"2","key":"848_CR71","doi-asserted-by":"publisher","first-page":"275","DOI":"10.24272\/j.issn.2095-8137.2023.199","volume":"45","author":"B Han","year":"2024","unstructured":"Han B, Liang W, Li X-J, Li S, Yan S, Tu Z (2024) Large animal models for huntington\u2019s disease research. Zool Res 45(2):275","journal-title":"Zool Res"},{"key":"848_CR72","unstructured":"Meglio M, Ciccone I (2025) Gene therapy, asos, and beyond: what\u2019s coming for huntington disease. Gene Ther"},{"issue":"8","key":"848_CR73","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11910-024-01345-y","volume":"24","author":"J Saade","year":"2024","unstructured":"Saade J, Mestre TA (2024) Huntington\u2019s disease: latest frontiers in therapeutics. Curr Neurol Neurosci Rep 24(8):255\u2013264","journal-title":"Curr Neurol Neurosci Rep"},{"key":"848_CR74","doi-asserted-by":"publisher","DOI":"10.1177\/11795735221092517","volume":"14","author":"MW Ferguson","year":"2022","unstructured":"Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RL, Kwakowsky A (2022) Current and possible future therapeutic options for huntington\u2019s disease. J Cent Nerv Syst Dis 14:11795735221092517","journal-title":"J Cent Nerv Syst Dis"},{"issue":"6","key":"848_CR75","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/hmg\/2.6.635","volume":"2","author":"YP Goldberg","year":"1993","unstructured":"Goldberg YP, Andrew SE, Clarke LA, Hayden MR (1993) A PCR method for accurate assessment of trinucleotide repeat expansion in huntington disease. Hum Mol Genet 2(6):635\u2013636","journal-title":"Hum Mol Genet"},{"issue":"3","key":"848_CR76","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/14737175.2024.2314183","volume":"24","author":"A Jurcau","year":"2024","unstructured":"Jurcau A, Simion A, Jurcau MC (2024) Emerging antibody-based therapies for huntington\u2019s disease: current status and perspectives for future development. Expert Rev Neurother 24(3):299\u2013312","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"848_CR77","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1007\/s12035-022-03150-5","volume":"60","author":"SS Alkanli","year":"2023","unstructured":"Alkanli SS, Alkanli N, Ay A, Albeniz I (2023) CRISPR\/Cas9 mediated therapeutic approach in huntington\u2019s disease. Mol Neurobiol 60(3):1486\u20131498","journal-title":"Mol Neurobiol"},{"issue":"11","key":"848_CR78","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s12264-022-00880-3","volume":"38","author":"Y Qin","year":"2022","unstructured":"Qin Y, Li S, Li X-J, Yang S (2022) CRISPR-based genome-editing tools for Huntington\u2019s disease research and therapy. Neurosci Bull 38(11):1397\u20131408","journal-title":"Neurosci Bull"},{"issue":"7","key":"848_CR79","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1172\/JCI92087","volume":"127","author":"S Yang","year":"2017","unstructured":"Yang S et al (2017) CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of huntington\u2019s disease. J Clin Invest 127(7):2719\u20132724","journal-title":"J Clin Invest"},{"issue":"4","key":"848_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18040754","volume":"18","author":"N Kolli","year":"2017","unstructured":"Kolli N, Lu M, Maiti P, Rossignol J, Dunbar GL (2017) CRISPR-Cas9 mediated gene-silencing of the mutant Huntingtin gene in an in vitro model of huntington\u2019s disease. Int J Mol Sci 18(4):754","journal-title":"Int J Mol Sci"},{"issue":"8","key":"848_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/genes16080850","volume":"16","author":"A Akbar","year":"2025","unstructured":"Akbar A et al (2025) CRISPR in neurodegenerative diseases treatment: an alternative approach to current therapies. Genes 16(8):850","journal-title":"Genes"},{"issue":"1","key":"848_CR82","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/0115665232292246240426125504","volume":"25","author":"B Bhushan","year":"2025","unstructured":"Bhushan B, Singh K, Kumar S, Bhardwaj A (2025) Advancements in CRISPR-based therapies for genetic modulation in neurodegenerative disorders. Curr Gene Ther 25(1):34\u201345","journal-title":"Curr Gene Ther"},{"issue":"7","key":"848_CR83","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ et al (2022) Potential disease-modifying therapies for huntington\u2019s disease: lessons learned and future opportunities. Lancet Neurol 21(7):645\u2013658","journal-title":"Lancet Neurol"},{"issue":"1","key":"848_CR84","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12038-023-00413-8","volume":"49","author":"P Bhattacharyya","year":"2024","unstructured":"Bhattacharyya P, Mehndiratta K, Maiti S, Chakraborty D (2024) Rare genetic disorders in India: current status, challenges, and CRISPR-based therapy. J Biosci 49(1):28","journal-title":"J Biosci"},{"issue":"2","key":"848_CR85","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2478\/jtim-2023-0142","volume":"12","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Zhang S, Shang H (2024) Latest advances on new promising molecular-based therapeutic approaches for huntington\u2019s disease. J Transl Intern Med 12(2):134\u2013147","journal-title":"J Transl Intern Med"},{"issue":"6","key":"848_CR86","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/hmg\/2.6.637","volume":"2","author":"O Riess","year":"1993","unstructured":"Riess O, Noerremoelle A, Soerensen SA, Epplen JT (1993) Improved PCR conditions for the stretch of (CAG) n repeats causing huntington\u2019s disease. Hum Mol Genet 2(6):637\u2013637","journal-title":"Hum Mol Genet"},{"issue":"11","key":"848_CR87","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/jmg.31.11.872","volume":"31","author":"K Kieburtz","year":"1994","unstructured":"Kieburtz K et al (1994) Trinucleotide repeat length and progression of illness in huntington\u2019s disease. J Med Genet 31(11):872\u2013874","journal-title":"J Med Genet"}],"container-title":["Neurogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-025-00848-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10048-025-00848-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-025-00848-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T05:02:02Z","timestamp":1769403722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10048-025-00848-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1007\/s10048-025-00848-1","relation":{},"ISSN":["1364-6753"],"issn-type":[{"value":"1364-6753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}